Research Brief
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer
Yijun Gao, Ann Maria, Na Na, Arnaud da Cruz Paula, Alexander N. Gorelick, Jaclyn F. Hechtman, Julianne Carson, Robert A. Lefkowitz, Britta Weigelt, Barry S. Taylor, HuiYong Zhao, Jorge S. Reis-Filho, Elisa de Stanchina, Neal Rosen, Zhan Yao and Rona Yaeger
Yijun Gao
Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Ann Maria
Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Na Na
Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Arnaud da Cruz Paula
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Alexander N. Gorelick
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Jaclyn F. Hechtman
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Julianne Carson
Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Robert A. Lefkowitz
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Britta Weigelt
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Barry S. Taylor
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
HuiYong Zhao
Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jorge S. Reis-Filho
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Elisa de Stanchina
Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.
Neal Rosen
Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Zhan Yao
Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Rona Yaeger
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
DOI: 10.1158/2159-8290.CD-19-0356 Published September 2019

Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't.
September 2019
Volume 9, Issue 9
Volume 9, Issue 9
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer
Yijun Gao, Ann Maria, Na Na, Arnaud da Cruz Paula, Alexander N. Gorelick, Jaclyn F. Hechtman, Julianne Carson, Robert A. Lefkowitz, Britta Weigelt, Barry S. Taylor, HuiYong Zhao, Jorge S. Reis-Filho, Elisa de Stanchina, Neal Rosen, Zhan Yao and Rona Yaeger
Cancer Discov September 1 2019 (9) (9) 1182-1191; DOI: 10.1158/2159-8290.CD-19-0356
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer
Yijun Gao, Ann Maria, Na Na, Arnaud da Cruz Paula, Alexander N. Gorelick, Jaclyn F. Hechtman, Julianne Carson, Robert A. Lefkowitz, Britta Weigelt, Barry S. Taylor, HuiYong Zhao, Jorge S. Reis-Filho, Elisa de Stanchina, Neal Rosen, Zhan Yao and Rona Yaeger
Cancer Discov September 1 2019 (9) (9) 1182-1191; DOI: 10.1158/2159-8290.CD-19-0356
Jump to section
Advertisement